HLB Targets Bile Duct Cancer with Exclusive RLY-4008 Licensing Deal

· HLB’s Eleva Therapeutics partners with Relay Therapeutics for breakthrough cancer drug

HLB targets bile duct cancer with exclusive RLY-4008 licensing deal (IT Times)

HLB is advancing its bile duct cancer treatment efforts with its U.S. subsidiary Eleva Therapeutics signing an exclusive licensing agreement with Relay Therapeutics for RLY-4008, an oral FGFR2-targeting drug. Having completed Phase 2 trials across 13 countries, RLY-4008 showed superior efficacy (57.9% objective response rate) and reduced side effects compared to existing treatments. Designated as a Breakthrough Therapy and Orphan Drug by the FDA, the drug is set for expedited regulatory submission in 2024, with potential expansion as a tumor-agnostic therapy for FGFR2-driven cancers. Building on its progress in liver cancer treatments, HLB plans to integrate RLY-4008 into its pipeline and explore combination therapies, aiming to solidify its position as a global healthcare leader by 2025.

Read more: https://www.ittimes.com/news/articleView.html?idxno=56792

HLB Targets Bile Duct Cancer with Exclusive RLY-4008 Licensing Deal - IT타임스